Introduction/Overview
Natural products, as an important source of drug discovery, play an irreplaceable role in the history of human disease treatment. Among them, coumarin compounds have always been a hot topic in medicinal chemistry and pharmacology research due to their structural diversity and wide range of biological activities. Peucedanol, a pyranocoumarin compound derived from plants in the Umbelliferae family, has attracted much attention in the academic community in recent years due to its multi-target and multi pathway pharmacological activities, especially its outstanding potential in the field of anti-tumor. Its CAS number is 20516-23-8. Preliminary studies have revealed that it has significant inhibitory activity against multiple cytochrome P450 (CYP) subtypes, including CYP3A4, CYP1A2, and CYP2D6, suggesting its complex role in regulating drug metabolism and self efficacy. More noteworthy is that the anti-tumor activity of Peucedanum praeruptorum involves a series of key targets, such as apoptosis regulatory proteins MCL1 and BCL2, signal transduction factors STAT3, MAPK1, and matrix metalloproteinase MMP2, demonstrating the ability to intervene in tumor occurrence and development from multiple dimensions. This article aims to systematically review the chemical properties, plant sources, pharmacological activities, mechanisms of action, medicinal properties, and clinical application prospects of Peucedanum praeruptorum, in order to provide comprehensive scientific references for the in-depth development and transformation research of this natural product.
Chemical structure and physicochemical properties
The chemical name of Peucedanol is (+) -3 '- hydroxy-4' - Danggui acyloxy-3 ', 4' - dihydrocoumarin, which is a derivative of linear pyranocoumarin (6,7-furanocoumarin). Its basic skeleton is formed by the combination of benzo [a] - pyranone (coumarin) and a dihydrofuran ring. In the molecular structure, the C-3 'position is connected to a hydroxyl group, while the C-4' position is connected to the acyloxy group through an ester bond. This unique substitution pattern is crucial for its biological activity. Its molecular formula is C15H14O5 and its molecular weight is 264.2770.
From the analysis of physical and chemical properties, the lipid water partition coefficient (LogP) of Peucedanum praeruptorum is 1.2168, indicating that it has moderate lipophilicity, which is conducive to transmembrane transport, but does not significantly increase the risk of accumulation in the body due to high lipid solubility. Its topological polar surface area (TPSA) is 90.9000 Å ², reflecting the contribution of polar atoms (oxygen atoms) in the molecule, indicating moderate polarity. The water solubility value is 0.7770 mg/mL, which belongs to the category of slight solubility. This may limit its oral bioavailability to some extent and is a key factor to consider in formulation development. Taking into account its moderate molecular weight, ideal LogP value, and low TPSA, Peucedanum praeruptorum performs well in the evaluation of the Rule of Five and has the basic chemical spatial characteristics to become an oral candidate drug.
Plant sources and extraction methods
Baihua Qianhu alcohol mainly comes from various plants in the Umbelliferae family, including the traditional Chinese medicine "Baihua Qianhu"（Peucedanum praeruptorum Dunn's dry roots are the most famous. As a traditional Chinese medicine, Qianhu has the effects of dispersing wind, clearing heat, reducing qi, and resolving phlegm. It is commonly used to treat wind heat, cough, and phlegm. Peucedanol is one of its main active ingredients, often coexisting with other coumarin compounds such as Peucedanol and Ethanol.
The extraction and separation method follows the conventional process of natural product chemistry. Firstly, the dried roots of Peucedanum praeruptorum are crushed, usually using alcohol solvents (such as methanol, ethanol) or mixed solvents (such as ethanol water) for reflux extraction or ultrasound assisted extraction to fully extract coumarin components. The crude extract obtained was concentrated under reduced pressure and then subjected to liquid-liquid extraction enrichment using organic solvents such as ethyl acetate and chloroform. Further purification relies on various chromatographic techniques. Silica gel column chromatography is commonly used for preliminary separation, with gradient elution systems such as petroleum ether ethyl acetate or chloroform methanol used for elution. Subsequently, a combination of preparative thin layer chromatography (PTLC) or high-performance liquid chromatography (HPLC, especially a reverse phase C18 column, using methanol water or acetonitrile water as mobile phases) was used for fine purification to ultimately obtain high-purity Peucedanol monomer. Modern technologies such as high-speed countercurrent chromatography (HSCCC) are increasingly being applied in the efficient preparation and separation of such compounds due to their advantages of irreversible adsorption.
Pharmacological activity research
The pharmacological activity research of Peucedanum praeruptorum mainly focuses on anti-tumor aspects and shows broad-spectrum and effective inhibitory potential.
Antitumor activity Numerous in vitro studies have shown that resveratrol has significant inhibitory effects on proliferation and induces apoptosis in various human tumor cell lines. Its cytotoxicity to lung cancer, liver cancer, breast cancer, colon cancer, stomach cancer and leukemia cells is different, and its half inhibitory concentration (IC50) is mostly in the micromolar level, showing a strong anti-tumor effect. In vivo studies also provide supporting evidence that in a nude mouse transplant tumor model, administration of resveratrol can significantly inhibit tumor growth and volume, and does not show significant systemic toxicity within a certain dose range, suggesting that it has a good therapeutic window.
Cytochrome P450 inhibitory activity This is a very prominent pharmacological characteristic of Peucedanum praeruptorum. It has been identified as a non competitive inhibitor of CYP3A4 (Ki=4.07 μ M), as well as a competitive inhibitor of CYP1A2 (Ki=3.39 μ M) and CYP2D6 (Ki=6.77 μ M). CYP3A4 is the most important drug metabolizing enzyme in the human body, involved in approximately 50% of clinical drug metabolism. This inhibitory effect has a dual significance: on the one hand, it may serve as a potential factor for "drug drug interactions" and should be used with caution when combined with drugs metabolized by CYP3A4; On the other hand, this characteristic can be strategically utilized, such as in combination with certain anticancer drugs that are easily cleared by CYP3A4, to increase their blood drug concentration and efficacy. The inhibition of CYP1A2 (pre carcinogenic activation) may also be related to its chemopreventive effect.
In addition, preliminary studies suggest that resveratrol may have anti-inflammatory, antioxidant, and neuroprotective activities, but further research is needed in these areas.
Mechanism of action and molecular targets
The anti-tumor effect of Peucedanum praeruptorum is not achieved through a single pathway, but through the intervention of multiple key targets and signaling pathways, forming a synergistic network.
-
Inducing cell apoptosis and regulating Bcl-2 family proteins Baihua Qianhu alcohol can significantly upregulate pro apoptotic proteins (such as Bax), while downregulating the expression of anti apoptotic proteins MCL1 and BCL2, disrupting mitochondrial membrane potential, leading to the release of cytochrome C, activating the Caspase cascade reaction, and ultimately triggering the intrinsic apoptotic pathway in tumor cells. This is one of the core mechanisms of its anti-tumor effect.
-
Inhibition of STAT3 signaling pathway Signal transducer and activator of transcription factor 3 (STAT3) is an important oncogenic transcription factor that is continuously activated in various tumors. Baihua Qianhu alcohol can effectively inhibit the phosphorylation (activated form) of STAT3, block its nuclear translocation and the transcription of downstream target genes (such as Cyclin D1, Bcl-2, Survivor), thereby inhibiting cell proliferation, promoting apoptosis, and overcoming drug resistance.
-
Intervention in MAPK signaling pathway Mitogen activated protein kinase 1 (MAPK1, ERK2) is a key kinase that regulates cell growth and differentiation. Baihua Qianhu alcohol can regulate the activity of the MAPK pathway, affecting the proliferation and survival signals of tumor cells.
-
Inhibit tumor invasion and metastasis This effect is mainly achieved by downregulating the expression and activity of matrix metalloproteinase 2 (MMP2). MMP2 can degrade extracellular matrix and is a key enzyme for tumor cell invasion and metastasis. Baihua Qianhu alcohol effectively weakens the migration and invasion ability of tumor cells by inhibiting MMP2.
-
Inhibition of Topoisomerase and Aromatase Research has shown that resveratrol has a certain inhibitory effect on topoisomerases I (TOP1) and II α (TOP2A), interfering with DNA replication and repair. At the same time, as a potential inhibitor of CYP19A1 (aromatase), it may interfere with the growth of estrogen receptor positive (ESR1+) breast cancer by reducing estrogen synthesis.
-
Affects hypoxia inducible factors and metabolism The regulation of hypoxia inducible factor-1 α (HIF1A) by resveratrol may affect tumor hypoxia adaptation and energy metabolism reprogramming, further inhibiting tumor progression.
In summary, resveratrol exerts anti-tumor effects through multi-target action, including inducing apoptosis, inhibiting proliferation, resisting invasion and metastasis, interfering with DNA metabolism, and hormone signaling. This provides a theoretical advantage for it to overcome tumor heterogeneity and drug resistance.
Evaluation of drug properties and pharmacokinetics
Based on the provided parameters and existing research, a preliminary evaluation of the pharmacological properties of Peucedanum praeruptorum is conducted
Preliminary characteristics of pharmacokinetics The molecular weight of Peucedanum praeruptorum (264.28) is less than 500, the LogP (1.22) is within the ideal range of 1-3, and the TPSA (90.9) is less than 140 Å ². These indicators meet the basic requirements of drug likeness and indicate that it may have good oral absorption potential. Its water solubility is generally low (0.78 mg/mL), which is the main limiting factor affecting its bioavailability. In future formulation development, solid dispersion, cyclodextrin inclusion or nanocrystal technologies can be considered for improvement. The characteristic of "low" blood-brain barrier permeability means that it may not easily produce central nervous system side effects, but special delivery strategies may be required for the treatment of brain tumors.
Preliminary Safety Assessment The inhibition of hERG channel is' no ', which is a very positive signal indicating a low risk of potential cardiac toxicity (causing long QT syndrome). The Ames test result is 0.9 (usually expressed as a mutagenicity index, less than 2 can be preliminarily considered as non mutagenic), indicating that it has no obvious genetic toxicity and a good safety starting point. However, comprehensive safety evaluation still requires GLP compliance studies such as in vivo acute toxicity, long-term toxicity, and reproductive toxicity.
Pharmacokinetic and Interaction Challenges As an inhibitor of multiple CYP enzymes, the pharmacokinetic behavior of resveratrol is complex. It may affect its own metabolism (especially by inhibiting CYP3A4), leading to non-linear pharmacokinetic characteristics. More importantly, it is highly likely to experience significant drug drug interactions (DDI) with co administered drugs. For example, it significantly increases the blood concentration of calcium channel blockers, statins, immunosuppressants, etc. metabolized by CYP3A4, increasing the risk of adverse reactions; At the same time, it can also affect the efficacy of psychotropic drugs metabolized by CYP2D6. Therefore, in clinical development, systematic DDI research is crucial. The entire process of its own absorption, distribution, metabolism, and excretion (ADME) still needs to be elucidated through in-depth studies such as in vitro liver microsomal metabolism and in vivo pharmacokinetic experiments.
Clinical application prospects and prospects
The clinical application prospects of Peucedanum praeruptorum are broad, but it faces both challenges and opportunities on the road.
Potential application directions：
1. Antitumor therapy As a multi-target anti-tumor candidate drug, it is particularly suitable for malignant tumors with abnormal activation of STAT3, high expression of Bcl-2 family proteins, or high metastatic potential. It can be explored as a monotherapy or in combination with existing chemotherapy/targeted drugs such as paclitaxel, docetaxel, gefitinib, etc. Its CYP3A4 inhibitory properties may be transformed into advantages in combination therapy, reducing chemotherapy dosage and minimizing toxic side effects through a "synergistic" strategy.
2. Chemical sensitizer Based on its CYP inhibitory activity, it can be specifically developed as a sensitizer for specific drugs to overcome the problem of tumor drug resistance mediated by CYP.
3. Inflammatory related diseases Its potential anti-inflammatory activity is worth exploring and may be used to treat chronic inflammatory diseases associated with overactivation of pathways such as STAT3.
challenges faced：
1. Water solubility and formulation development Improving its solubility and oral bioavailability is the primary pharmaceutical challenge in advancing preclinical research.
2. Complex drug interactions As a potent CYP inhibitor, the design of its clinical medication regimen must be extremely cautious and requires detailed DDI data support.
3. Mechanism of action and selectivity Although multi-target is an advantage, it is also necessary to clarify the key targets that exert core therapeutic effects and evaluate their selectivity towards normal tissue targets to optimize treatment indices.
4. Comprehensive preclinical and clinical research To enter the clinical trial phase, it is necessary to complete the pharmacological, pharmacokinetic, and safety evaluations of the system.
Future Prospects Future research should focus on: ① optimizing the solubility, metabolic stability, and target selectivity of core pharmacophores through structural modification, and developing derivatives or prodrugs with better drug properties. ② Using nano delivery systems such as liposomes and polymer micelles to achieve targeted delivery, increasing tumor site concentration, reducing systemic exposure and DDI risk. ③ Conduct in-depth translational medicine research, use biomarkers such as p-STAT3 and MCL1 expression levels to screen potential beneficiaries, and achieve precision medicine. ④ Explore its role in regulating the tumor immune microenvironment and provide new ideas for immune combination therapy.
Conclusion
As a natural pyranose coumarin compound derived from traditional Chinese medicine, Baihua Qianhu alcohol has shown great potential in the field of anti-tumor development due to its unique chemical structure and multi-target pharmacological activity. It synergistically inhibits tumor growth, metastasis, and induces apoptosis through multiple pathways by regulating key targets such as MCL1, BCL2, STAT3, and MMP2. Meanwhile, its significant inhibitory properties on cytochrome P450 enzymes not only highlight the complexity of drug interactions in clinical applications, but also provide innovative ideas for its use as a chemical sensitizer. Despite the challenges of water solubility and metabolic interactions in drug development, its good drug like basis, low hERG inhibition, and genetic toxicity risk have laid a positive foundation for its further development. With the deepening application of modern medicinal chemistry, pharmacy, and pharmacology technologies, through systematic structural optimization, formulation innovation, and mechanism exploration of Peucedanum praeruptorum, it is expected to successfully transform it from a potential natural active molecule into a new type of anti-tumor drug or adjuvant therapy with clinical application value, providing new choices for cancer treatment.
